Overcoming the novel glycan-lectin checkpoints in tumor microenvironment for the success of the cross-presentation-based immunotherapy

Biomater. Sci., 2025, Accepted Manuscript
DOI: 10.1039/D4BM01732C, Review Article

Open Access

&nbsp This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

Mannat Jain, Isha M Jadhav, Suyash Vinayak Dangat, Srinivasa Rao Singuru, Gautam Sethi, Eiji Yuba, Rajesh Kumar Gupta
In pursuit of meeting the ever-rising demand for cancer therapies, cross-presentation-based glyconanovaccines (GNVs) targeting C-type lectin receptors (CLRs) on DCs have shown significant potential as cutting-edge cancer immunotherapy. GNVs are...
The content of this RSS Feed (c) The Royal Society of Chemistry